目的:分析对2型糖尿病患者实施恩格列净联合格列齐特治疗的临床价值。方法:选择我院2021年7月-2022年8月，期间内分泌门诊就诊的134例2型糖尿病患者，将所有患者随机分组为对照组（67例，采用恩格列净治疗）和试验组（67例，实施恩格列净联合格列齐特治疗）。结果:试验组治疗效果明显高于对照组，试验组肾功能明显优于对照组，试验组血糖水平明显低于对照组，差异均有统计学意义（P＜0.05），两组不良反发生率差异无统计学意义（P＞0.05）。结论:对2型糖尿病患者实施恩格列净联合格列齐特治疗效果更佳，可有效维持

Objective:To investigate the effect of dapagliflozin on aldosterone to renin ratio (ARR) in patients with type 2 diabetes mellitus (T2DM) complicated with hypertension.Methods:Patients with T2DM and hypertension who were admitted to the Department of Endocrinology, Beijing Huairou Hospital from September 2019 to December 2020 were enrolled. Body weight, fasting blood glucose (FPG), glycosylated hemoglobin (HbA 1c), uric acid, plasma renin concentration, aldosterone level and other indicators were measured and recorded before treatment, and ARR was calculated. Patients were treated with dapagliflozin for 12 weeks, and hematologic indicators were collected again while ARR was also calculated. Paired t test or Mann-Whitney U test were used to compare the ARR and related indexes before and after treatment of dapagliflozin. Results:A total of 20 patients were enrolled. ARR before and after treatment were 0.86 (0.73, 1.20) and 0.95 (0.72, 1.32), respectively. However, there was no significant difference between them ( Z=1.12, P=0.263). After 12 weeks of dapagliflozin, FPG ( Z=-3.62, P<0.001), HbA 1c ( Z=-3.76, P<0.001), body weight ( Z=-3.19, P=0.001) and uric acid ( Z=-2.71, P=0.014) decreased significantly compared with baseline. Conclusions:Dapagliflozin has no effect on ARR in patients with T2DM complicated with hypertension, but it has good effects on reducing FPG, uric acid and weight loss.

目的 探究顺尔宁与欧龙马滴剂应用在上气道综合征患者治疗中的临床效果.方法 将我院收治的40例上气道综合征患者作为研究对象,并分为观察组和对照组各20例,观察组采用顺尔宁与欧龙马滴剂联合治疗,对照组采用欧龙马滴剂治疗,对比两组治患者疗效果.结果 观察组患者各项症状缓解情况显著优于对照组;同时观察组患者治疗有效为95%,显著高于对照组的85%,组间差异存在统计学意义(P<0.05).结论 顺尔宁与欧龙马滴剂应用在上气道综合征治疗中效果显著,患者病情改善良好,值得临床推广运用.